In silico classification of major clearance pathways of drugs with their physiochemical parameters

Drug Metabolism and Disposition

Volumn 38, Issue 8, 2010, Pages 1362-1370

  Kusama, Makiko ^a   Toshimoto, Kouta ^b   Maeda, Kazuya ^a   Hirai, Yuka ^a   Imai, Satoki ^a   Chiba, Koji ^c   Akiyama, Yutaka ^b   Sugiyama, Yuichi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b TOKYO INSTITUTE OF TECHNOLOGY   (Japan)

^c KEIO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CHLOROQUINE; CHLORPROMAZINE; CLONAZEPAM; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DICLOXACILLIN; DIPHENHYDRAMINE; DOXEPIN; ENALAPRIL; FLECAINIDE; FLUOXETINE; FLUPHENAZINE; GLIMEPIRIDE; GLIPIZIDE; GRANISETRON; IFOSFAMIDE; IMIPRAMINE; METOPROLOL; NORTRIPTYLINE; ORGANIC ANION TRANSPORTER; PRAVASTATIN; RIFAMPICIN; RISPERIDONE; ROSUVASTATIN; TEMOCAPRILAT; TIMOLOL; TOLTERODINE; UNINDEXED DRUG;

ARTICLE; DRUG CLEARANCE; DRUG INFORMATION; LIPOPHILICITY; MOLECULAR WEIGHT; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; URINARY EXCRETION;

COMPUTATIONAL BIOLOGY; COMPUTER SIMULATION; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; PHYSICOCHEMICAL PROCESSES;

EID: 77954917978     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.110.032789     Document Type: Article

References (21)

1. Benet LZ, Oie S, and Swharts JB (1996) Design and optimization of dosage regimens: pharmacokinetic data, in Goodman & Gilman's The Pharmacological Basis of Therapeutics (Good-man LS, Gilman A, Hardman JG, Gilman AG, and Limbird LE eds), 9th ed, pp 1707-1792, McGraw-Hill, Health Professions Division, New York.
2. Hirom PC, Millburn P, Smith RL, and Williams RT (1972) Species variations in the threshold molecular-weight factor for the biliary excretion of organic anions. Biochem J 129:1071-1077.
3. Ingelman-Sundberg M (2005) Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J 5:6-13.
4. Kirchheiner J, Roots I, Goldammer M, Rosenkranz B, and Brockmöller J (2005) Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance. Clin Pharmacokinet 44:1209-1225.
5. Lewis DF (2000) On the recognition of mammalian microsomal cytochrome P450 substrates and their characteristics: towards the prediction of human p450 substrate specificity and metabolism. Biochem Pharmacol 60:293-306.
6. Lewis DF and Dickins M (2002) Substrate SARs in human P450s. Drug Discov Today 7:918-925.
7. Lipinski CA (2003) Chris Lipinski discusses life and chemistry after the Rule of Five. Drug Discov Today 8:12-16.
8. Naritomi Y, Terashita S, and Kagayama A (2004) Identification and relative contributions of human cytochrome P450 isoforms involved in the metabolism of glibenclamide and lansoprazole: evaluation of an approach based on the in vitro substrate disappearance rate. Xenobiotica 34:415-427. (Pubitemid 38901452)
9. SEARCH Collaborative Group, Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, Gut I, Lathrop M, and Collins R (2008) SLCO1B1 variants and statin-induced myopathy-a genomewide study. N Engl J Med 359:789-799.
10. Shitara Y, Hirano M, Sato H, and Sugiyama Y (2004) Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. J Pharmacol Exp Ther 311:228-236.
11. Shitara Y and Sugiyama Y (2006) Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther 112:71-105.
12. Smith DA (1991) Species differences in metabolism and pharmacokinetics: are we close to an understanding? Drug Metab Rev 23:355-373.
13. Smith DA and Jones BC (1992) Speculations on the substrate structure-activity relationship (SSAR) of cytochrome P450 enzymes. Biochem Pharmacol 44:2089-2098.
14. Takagi T, Ramachandran C, Bermejo M, Yamashita S, Yu LX, and Amidon GL (2006) A provisional biopharmaceutical classification of the top 200 oral drug products in the United States, Great Britain, Spain, and Japan. Mol Pharm 3:631-643. (Pubitemid 46087480)
15. Thummel KE and Shen DD (2001) Design and optimization of dosage regimens: pharmacokinetic data, in Goodman & Gilman's The Pharmacological Basis of Therapeutics (Gilman A and Goodman LS eds), 10th ed, pp 1917-2024, McGraw-Hill Medical Publishing Division, New York.
16. Thummel KE, Shen DD, Isoherranen N, and Smith HE (2006) Design and optimization of dosage regimens: pharmacokinetic data, in Goodman & Gilman's The Pharmacological Basis of Therapeutics (Gilman AG, Brunton LL, Gilman A, Goodman LS, Lazo JS, and Parker KL eds), 11th ed, pp 1787-1888, McGraw-Hill Medical Publishing Division, New York.
17. Williams JA, Hyland R, Jones BC, Smith DA, Hurst S, Goosen TC, Peterkin V, Koup JR, and Ball SE (2004) Drug-drug interactions for UDP- glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos 32:1201-1208.
18. Wu CY and Benet LZ (2005) Predicting drug disposition via application of BCS: transport/ absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res 22:11-23.
19. Yamashita F, Hara H, Ito T, and Hashida M (2008) Novel hierarchical classification and visualization method for multiobjective optimization of drug properties: application to structure-activity relationship analysis of cytochrome P450 metabolism. J Chem Inf Model 48:364-369.
20. Yang X, Gandhi YA, Duignan DB, and Morris ME (2009) Prediction of biliary excretion in rats and humans using molecular weight and quantitative structure-pharmacokinetic relationships. AAPS J 11:511-525.
21. Yu LX, Amidon GL, Polli JE, Zhao H, Mehta MU, Conner DP, Shah VP, Lesko LJ, Chen ML, Lee VH, et al. (2002) Biopharmaceutics classification system: the scientific basis for biowaiver extensions. Pharm Res 19:921-925.